Next Article in Journal
The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients’ Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers
Next Article in Special Issue
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
Previous Article in Journal
Tunnelled Peritoneal Catheter for Malignant Ascites—An Open-Label, Prospective, Observational Trial
Previous Article in Special Issue
Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer
 
 
Review

Article Versions Notes

Cancers 2021, 13(12), 2924; https://doi.org/10.3390/cancers13122924
Action Date Notes Link
article xml file uploaded 11 June 2021 11:43 CEST Original file -
article xml uploaded. 11 June 2021 11:43 CEST Update https://www.mdpi.com/2072-6694/13/12/2924/xml
article pdf uploaded. 11 June 2021 11:43 CEST Version of Record https://www.mdpi.com/2072-6694/13/12/2924/pdf
article html file updated 11 June 2021 11:45 CEST Original file -
article html file updated 26 July 2022 23:53 CEST Update https://www.mdpi.com/2072-6694/13/12/2924/html
Back to TopTop